{
    "organizations": [],
    "uuid": "cac64511d1f49f59ed67152ea9673c0aabe67e88",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/02/globe-newswire-fibrogen-to-report-first-quarter-2018-financial-results-on-wednesday-may-9-2018.html",
    "ord_in_thread": 0,
    "title": "FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAN FRANCISCO, May 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018, after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).\nConference Call and Audio Webcast\nInterested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com . It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 46778299#.\nDial-In Information\nLive (U.S./Canada): (888) 771-4371\nLive (International): (847) 585-4405\nConfirmation number: 46778299#\nAbout FibroGen\nFibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), except in China, where a New Drug Application is currently under review by the China Food and Drug Administration (recently reformed as the State Drug Administration, or SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe, and expected to shortly enter Phase 2/3 development in China, for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com .\nContact\nFibroGen, Inc.\nKaren L. Bergman\nVice President, Investor Relations and Corporate Communications\n1 (415) 978-1433\nkbergman@fibrogen.com\nSource:FibroGen, Inc",
    "published": "2018-05-02T15:00:00.000+03:00",
    "crawled": "2018-05-02T15:35:12.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "san",
        "francisco",
        "may",
        "globe",
        "newswire",
        "fibrogen",
        "nasdaq",
        "fgen",
        "biopharmaceutical",
        "company",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "wednesday",
        "may",
        "market",
        "close",
        "host",
        "conference",
        "call",
        "discus",
        "financial",
        "result",
        "provide",
        "business",
        "update",
        "et",
        "pt",
        "conference",
        "call",
        "audio",
        "webcast",
        "interested",
        "party",
        "may",
        "access",
        "live",
        "audio",
        "webcast",
        "conference",
        "call",
        "via",
        "investor",
        "section",
        "fibrogen",
        "website",
        "recommended",
        "listener",
        "access",
        "website",
        "minute",
        "prior",
        "start",
        "call",
        "download",
        "install",
        "necessary",
        "audio",
        "software",
        "replay",
        "webcast",
        "available",
        "shortly",
        "call",
        "period",
        "two",
        "week",
        "access",
        "replay",
        "please",
        "dial",
        "domestic",
        "international",
        "use",
        "passcode",
        "information",
        "live",
        "live",
        "international",
        "confirmation",
        "number",
        "fibrogen",
        "fibrogen",
        "headquartered",
        "san",
        "francisco",
        "california",
        "subsidiary",
        "office",
        "beijing",
        "shanghai",
        "people",
        "republic",
        "china",
        "leading",
        "biopharmaceutical",
        "company",
        "discovering",
        "developing",
        "pipeline",
        "therapeutic",
        "company",
        "applies",
        "pioneering",
        "expertise",
        "factor",
        "hif",
        "connective",
        "tissue",
        "growth",
        "factor",
        "ctgf",
        "biology",
        "clinical",
        "development",
        "advance",
        "innovative",
        "medicine",
        "treatment",
        "anemia",
        "fibrotic",
        "disease",
        "cancer",
        "roxadustat",
        "company",
        "advanced",
        "product",
        "candidate",
        "oral",
        "small",
        "molecule",
        "inhibitor",
        "hif",
        "prolyl",
        "hydroxylase",
        "activity",
        "worldwide",
        "phase",
        "clinical",
        "development",
        "treatment",
        "anemia",
        "chronic",
        "kidney",
        "disease",
        "ckd",
        "except",
        "china",
        "new",
        "drug",
        "application",
        "currently",
        "review",
        "china",
        "food",
        "drug",
        "administration",
        "recently",
        "reformed",
        "state",
        "drug",
        "administration",
        "sda",
        "roxadustat",
        "phase",
        "clinical",
        "development",
        "europe",
        "expected",
        "shortly",
        "enter",
        "phase",
        "development",
        "china",
        "anemia",
        "associated",
        "myelodysplastic",
        "syndrome",
        "md",
        "pamrevlumab",
        "monoclonal",
        "antibody",
        "advancing",
        "towards",
        "phase",
        "clinical",
        "development",
        "treatment",
        "idiopathic",
        "pulmonary",
        "fibrosis",
        "ipf",
        "pancreatic",
        "cancer",
        "currently",
        "phase",
        "trial",
        "duchenne",
        "muscular",
        "dystrophy",
        "dmd",
        "fibrogen",
        "also",
        "developing",
        "biosynthetic",
        "cornea",
        "china",
        "information",
        "please",
        "visit",
        "contact",
        "fibrogen",
        "karen",
        "bergman",
        "vice",
        "president",
        "investor",
        "relation",
        "corporate",
        "communication",
        "kbergman",
        "source",
        "fibrogen",
        "inc"
    ]
}